The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.
 
Julie R. Brahmer
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; Janssen Oncology; Lilly; Merck; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
Other Relationship - Bristol-Myers Squibb; merck
 
Melissa Lynne Johnson
Consulting or Advisory Role - Araxes Pharma (Inst); Astellas Pharma (I); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Syndax (Inst); Syndax (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Merck; Pfizer; Sysmex; Vapotherm
 
Manuel Cobo Dols
No Relationships to Disclose
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Roche
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - Merck Serono (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Roche; SERVIER
 
Juan Coves
No Relationships to Disclose
 
Ammar Sukari
Consulting or Advisory Role - Bayer; Eisai
Speakers' Bureau - Eisai; Merck
Research Funding - Eisai
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb
 
Ravi Salgia
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
Arun Rajan
No Relationships to Disclose
 
Alicia Jones Allred
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Mark Wade
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Gary Mason
Employment - Janssen Research & Development
Travel, Accommodations, Expenses - Janssen Research & Development
 
Enrique Zudaire
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Nicole L. Stone
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Matthew V. Lorenzi
Employment - Bristol-Myers Squibb (I); Johnson & Johnson
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Johnson & Johnson
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst)